GC Pharma [Green Cross Corporation] (KRX: 006280) is a biopharmaceutical company headquartered in Yongin, South Korea. GC Pharma specializes in the development and commercialization of vaccines, protein therapies, and therapeutic antibodies for use in the fields of oncology and infectious disease. GC Pharma was established as "Sudo Microorganism Medical Supplies Co." in 1967, and changed the name to "Green Cross" in 1971. The company is engaged in research, development, manufacturing and sales of biotherapeutics, including plasma proteins, recombinant antibodies, and vaccines. Green Cross developed "Hepavax B", the world's third hepatitis B vaccine, in 1983, the world's first vaccine “Hantavax” against epidemic hemorrhagic fever in 1988, the world's second varicella vaccine in 1995, "Greengene", the world's 4th recombinant antihemophilic drug, and the world's second treatment of Hunter syndrome “Hunterase” in 2012. More information...
According to PR-model, greencross.com is ranked 1,018,324th in multilingual Wikipedia, in particular this website is ranked 572,244th in English Wikipedia.
The website is placed before edu.edu.pl and after 8box.ir in the BestRef global ranking of the most important sources of Wikipedia.
